Promoting Peace of Mind in the Global Supply Chain
segunda-feira, 23 de maio de 2011
terça-feira, 17 de maio de 2011
NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C
J Hepatol. 2010 Dec 15. [Epub ahead of print]
Asselah T.
Service d'hépatologie, Hôpital Beaujon, APHP, University Paris 7 Denis Diderot and INSERM, U773, CRB3, and Clichy, France.
Abstract
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we describe the profile of BMS-790052, a small molecule cialis of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC(50)) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.
Copyright © 2010. Published by Elsevier B.V.
PMID: 21167889 [PubMed - as supplied by publisher]
Source
Asselah T.
Service d'hépatologie, Hôpital Beaujon, APHP, University Paris 7 Denis Diderot and INSERM, U773, CRB3, and Clichy, France.
Abstract
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B. Here we describe the profile of BMS-790052, a small molecule cialis of the HCV NS5A protein that exhibits picomolar half-maximum effective concentrations (EC(50)) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture. In a phase I clinical trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was associated with a 3.3 log(10) reduction in mean viral load measured 24 h post-dose that was sustained for an additional 120 h in two patients infected with genotype 1b virus. Genotypic analysis of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants observed had substitutions at amino-acid positions identified using the in vitro replicon system. These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.
Copyright © 2010. Published by Elsevier B.V.
PMID: 21167889 [PubMed - as supplied by publisher]
Source
terça-feira, 3 de maio de 2011
Tablets grab share of PC market
purchase cialis, smartphones, and other mobile devices are making serious inroads into the business computing marketplace. cheap cialis in particular are seen as giving employees choice and flexibility in doing most of the simpler types of business computing. A recent bulletin from research firm Gartner, suggests that business leaders are open to the potential competitive advantage that mobile applications can bring. One result is their prediction that tablets are headed for the business enterprise "in a big way."
This potential is also behind the recent reduction in analysts' predictions of worldwide PC market growth from 9% to 4%. With Microsoft at least a year away from a tablet OS, and the larger PC manufacturer's having difficulty producing tablets competitive with the iPad, this gives Apple a head start on the future "business mobile" market..
Source: "Microsoft Could Lose More Than Consumer Market to Tablets," Information Week
This potential is also behind the recent reduction in analysts' predictions of worldwide PC market growth from 9% to 4%. With Microsoft at least a year away from a tablet OS, and the larger PC manufacturer's having difficulty producing tablets competitive with the iPad, this gives Apple a head start on the future "business mobile" market..
Source: "Microsoft Could Lose More Than Consumer Market to Tablets," Information Week
Viagra
Today is day 2 of cheap cialis suppositories. I am instructed to put in one suppository four times a day. To say they are gross, would be an understatement. I constantly feel as if I am leaking or dripping all day long. Because the cialis is inclosed in wax, it is the wax that dissolves and leaves you wanting a diaper...almost. Seriously though, I think I wear two liners at a time and I still feel gross.
Joke of the day...
Viagra cut into four
An elderly gentleman went to the local drug store and asked the pharmacist for Viagra.
The pharmacist said "That`s no problem. How many do you want?"
The man replied, "Just a few, maybe a half dozen, but can you cut each one into four pieces."
The pharmacist said, "That`s too small a dose. That won`t get you through sex."
The gentleman said, "Oh, that`s all right. I`m past eighty years old, and I don`t even think about sex anymore. I just want it to stick out far enough so I don`t pee on my shoes.
I wish I had the sex drive side effect, instead of feeling like I'm dripping on my shoes.
-R.
Joke of the day...
Viagra cut into four
An elderly gentleman went to the local drug store and asked the pharmacist for Viagra.
The pharmacist said "That`s no problem. How many do you want?"
The man replied, "Just a few, maybe a half dozen, but can you cut each one into four pieces."
The pharmacist said, "That`s too small a dose. That won`t get you through sex."
The gentleman said, "Oh, that`s all right. I`m past eighty years old, and I don`t even think about sex anymore. I just want it to stick out far enough so I don`t pee on my shoes.
I wish I had the sex drive side effect, instead of feeling like I'm dripping on my shoes.
-R.
Assinar:
Postagens (Atom)